ARTICLE | Clinical News
Betabloc (AN1792): Began Phase I trial
March 20, 2000 8:00 AM UTC
Elan Corp. plc (ELN), Dublin, Ireland Product: Betabloc (AN1792) Business: Neurological Therapeutic category: Immune stimulation Target: Immune cells Description: Beta amyloid 42-amino acid peptide v...